Value
6.6/10data confidence 83%| Component | Sub-score |
|---|---|
| P/S | 6.3 |
| EV/EBITDA | 0.0 |
| Fwd P/E | 7.7 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 15.9x
- ▸PEG: 0.02
HROW · Why this verdict
Why Harrow (HROW) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.1/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
A specialty pharmaceutical business with recovering price momentum carries a portfolio of structural weaknesses — cash-burning operations, no measurable competitive moat, a combined growth-plus-margin profile of negative 9, and revenue declining 8% year-over-year — that keep it below the minimum quality threshold required to build a position; the analyst community's implied 51% upside may reflect a turnaround hope that the fundamentals have not yet validated.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow is negative at 2% of revenue, no competitive moat is identified, and the combined growth-plus-margin profile comes in at negative 9 — a set of quality signals that together fall well below the floor required to underwrite a position. Quality breakdown | For quality to reach a minimum acceptable level, free cash flow should turn positive and the combined growth-plus-margin metric should recover above 0 for at least 2 consecutive quarters. | →Stable |
| CounterThe gross margin component scores at the top of its range, the Piotroski score comes in at 7 out of 9, and price momentum has recovered sufficiently to clear the momentum gate; quality may be in transition rather than permanently impaired. | ||
Revenue declined 8% year-over-year, turning the top line negative at a point when the business is also burning cash — a combination that compresses the runway for a self-funded recovery without external capital. Growth breakdown | If the growth trajectory reverses, revenue should turn positive for 2 consecutive quarters, demonstrating the contraction was transitory rather than structural. | →Stable |
| CounterThe forward P/E of 14.5x and PEG of 0.02 suggest the market is pricing in a rapid earnings recovery; if specialty drug volumes rebound, the revenue decline may prove to be a one-year reset rather than a durable trend. | ||
The two most recently reported quarters each missed consensus estimates — the most recent by 124% below expectations, the prior by 54% — erasing the momentum from two earlier beats and raising the question of whether guidance is a reliable guide to actual delivery. Earnings | If execution stabilizes, EPS should beat or meet consensus estimates in the next 2 reported quarters, reversing the recent miss streak. | →Stable |
| CounterThe two quarters prior to the recent misses produced substantial beats of 14% and 586% respectively, and the average surprise across all four quarters remains strongly positive; the miss pattern may be episodic rather than a sustained failure of execution. | ||
Short interest stands at 20% of float, and the put-to-call ratio of 1.71 signals that a broad swath of market participants are positioned for further downside — a level of aggregate skepticism that typically requires a catalyst strong enough to force meaningful short covering. Risk breakdown | If market sentiment improves, short interest should fall below 10% and the put-to-call ratio should compress below 1.0 over the next 6 months as fundamental improvement erodes the bear thesis. | →Stable |
| CounterElevated short interest can create a squeeze dynamic when news surprises to the upside; with 51% upside to analyst targets, any positive earnings surprise or pipeline event could compress short positions rapidly and drive outsized price appreciation. | ||
Free cash flow is negative at 2% of revenue, no competitive moat is identified, and the combined growth-plus-margin profile comes in at negative 9 — a set of quality signals that together fall well below the floor required to underwrite a position.
→StableQuality breakdown
- Expectation
- For quality to reach a minimum acceptable level, free cash flow should turn positive and the combined growth-plus-margin metric should recover above 0 for at least 2 consecutive quarters.
CounterThe gross margin component scores at the top of its range, the Piotroski score comes in at 7 out of 9, and price momentum has recovered sufficiently to clear the momentum gate; quality may be in transition rather than permanently impaired.
Revenue declined 8% year-over-year, turning the top line negative at a point when the business is also burning cash — a combination that compresses the runway for a self-funded recovery without external capital.
→StableGrowth breakdown
- Expectation
- If the growth trajectory reverses, revenue should turn positive for 2 consecutive quarters, demonstrating the contraction was transitory rather than structural.
CounterThe forward P/E of 14.5x and PEG of 0.02 suggest the market is pricing in a rapid earnings recovery; if specialty drug volumes rebound, the revenue decline may prove to be a one-year reset rather than a durable trend.
The two most recently reported quarters each missed consensus estimates — the most recent by 124% below expectations, the prior by 54% — erasing the momentum from two earlier beats and raising the question of whether guidance is a reliable guide to actual delivery.
→StableEarnings
- Expectation
- If execution stabilizes, EPS should beat or meet consensus estimates in the next 2 reported quarters, reversing the recent miss streak.
CounterThe two quarters prior to the recent misses produced substantial beats of 14% and 586% respectively, and the average surprise across all four quarters remains strongly positive; the miss pattern may be episodic rather than a sustained failure of execution.
Short interest stands at 20% of float, and the put-to-call ratio of 1.71 signals that a broad swath of market participants are positioned for further downside — a level of aggregate skepticism that typically requires a catalyst strong enough to force meaningful short covering.
→StableRisk breakdown
- Expectation
- If market sentiment improves, short interest should fall below 10% and the put-to-call ratio should compress below 1.0 over the next 6 months as fundamental improvement erodes the bear thesis.
CounterElevated short interest can create a squeeze dynamic when news surprises to the upside; with 51% upside to analyst targets, any positive earnings surprise or pipeline event could compress short positions rapidly and drive outsized price appreciation.
Per-dimension breakdown
Quality
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 2.1 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 8.4 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -2% of revenue
- ▸No competitive moat
- ▸Rule of 40: -9 (fail)
Growth
0.6/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.6 |
- ▸Declining revenue: -8%
Momentum
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.1 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 7.5 |
| Volume | 0.0 |
- ▸Overbought (RSI 78)
- ▸Volume distribution (falling OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 78 (late-cycle distribution risk)
Sentiment
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.9 |
| Price target | 9.7 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 60%
Insider
6.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 6.5 |
| insider conviction | 8.0 |
| holder change | 5.0 |
- ▸Modest insider buying — $468,720 (0.029% of mkt cap)
Peer rank
0.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.1 |
| quality rank | 1.1 |
| growth rank | 1.1 |
Technical
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.8 |
| support resistance | 1.8 |
| 52w position | 5.4 |
Risk (lower is worse)
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.5 |
| days to cover | 3.8 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 1.5 |
| max pain risk | 7.0 |
| beta | 10.0 |
| debt equity | 0.0 |
- ▸High short interest justified: 20%
- ▸Elevated put/call: 2.46
- ▸High IV: 71%
Catalyst
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:4.5>=4.5
- ASYMMETRY:2.6>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:46d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- MOMENTUM:4.5<5.5 (soft — BUY_NOW allowed but watch)
Reward-to-Risk
2.62
Upside
+39.3%
Downside
15.0%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 78
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.6B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.7 could not lift the engine output above the verdict floor. Failed gate signal: DEATH_CROSS:HARD_BLOCK.
The strongest dimensions are Sentiment at 7.7, Value at 6.6, and Insider at 6.5; the weakest are Growth at 0.6, Peer rank at 0.8, and Risk (lower is worse) at 3.0. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of 2.62 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Free cash flow is negative at 2% of revenue, no competitive moat is identified, and the combined growth-plus-margin profile comes in at negative 9 — a set of quality signals that together fall well below the floor required to underwrite a position.
Trip ifFree cash flow turns positive for 2 consecutive quarters and the combined growth-plus-margin metric rises above 0.
- P2Revenue declined 8% year-over-year, turning the top line negative at a point when the business is also burning cash — a combination that compresses the runway for a self-funded recovery without external capital.
Trip ifRevenue growth rises above 0% year-over-year for 2 consecutive quarters.
- P3The two most recently reported quarters each missed consensus estimates — the most recent by 124% below expectations, the prior by 54% — erasing the momentum from two earlier beats and raising the question of whether guidance is a reliable guide to actual delivery.
Trip ifEPS beats consensus by more than 5% in 2 consecutive quarters.
- P4Short interest stands at 20% of float, and the put-to-call ratio of 1.71 signals that a broad swath of market participants are positioned for further downside — a level of aggregate skepticism that typically requires a catalyst strong enough to force meaningful short covering.
Trip ifShort interest falls below 10% from the current 20% and the put-to-call ratio compresses below 1.0.